PHARMANEST EXECUTIVES:

MATHIEU

Mathieu M. Petitjean, Ph.D.

CEO

Li Chen, Ph.D.

Principal Investigator

Philippe Nore, MBA

Chief Business Officer

 

PHARNANEST BOARD OF DIRECTORS

Mathieu M. Petitjean, Ph.D.

Chairman and CEO

Pierre Claverie, Ph.D

Scalability and Resilience

Philippe Nore, MBA

Growth and Price

Henry Chang

Patient and Customer Advocate

CLINICAL AND MEDICAL ADVISORY BOARD

Pr. Vlad Ratziu, MD

Hepatologist

Hospital Pitié Salpêtrière, Paris

Pr. Arun J. Sanyal, MD

Hepatologist

Virginia Commonwealth University

 

Pr. Aras Mattis, MD, PhD

Gastrointestinal, Hepatobiliary Pathologist

U.C. San Francisco

Dr. Cynthia Behling, MD

Gastrointestinal, Hepatobiliary Pathologist

U.C. San Diego, Sharp Memorial Hospital

Pr. Mojgan Hosseini, MD

Gastrointestinal,Hepatobiliary Pathologist

U.C. San Diego

To be Announced


NEWS AND UPDATES (2025)

Check our news archive here

September 11, 2025: PharmaNest, NIH and VCU Launch Confirmatory Retrospective Outcome Study With 1,765 Patients to Advance AI-Driven Digital Pathology in MASLD, Press release here

May 7-10, 2025: PharmaNest to present five digital Pathology and abstracts at the 2025 EASL Congress in Amsterdam, EU in collaboration with major Academic center and pharmaceutical companies developing a cure for MASH, Alcoholic Liver Disease and Cirrhosis. Press Release Here.

May 3-6, 2025: PharmaNest attends the 2025 Digestive Disease Week (DDW) in San Diego, USA to develop strategic relationships with pharmaceutical companies exploring anti-fibrotic claims in Crohn’s Disease.

May 1, 2025: PharmaNest Launches FibroMAP, the First Single-Fiber Phenotypic Tool for the Study of Fibrosis Across Biological Models and Indications. Press Release Here.

January 12-14, 2025: PharmaNest attends the 2025 JP Morgan Healthcare Conference to develop strategic relationships in the Drug Development and Investors communities.

January, 11 2025: PharmaNest to present at the 2025 MASH-Tag Conference (Deer Park, UT, USA): Along side with Dr. Andy Beck (PathAI), Dr. Dean Tai (Histoindex), Prs. Mary Rinella, Vlad Ratziu and Naim Alkhouri, Dr. Mathieu Petitjean presents PharmaNest’s contributions to “Recent Progress in Measuring Antifibrotic Effects: Data from MASH Clinical Trials” (Presentation here)


Offices:

100 Overlook Center, FL2, Princeton, NJ 08540

FibroNest Operations:

We deliver FibroNest worldwide via the Cloud.

Privacy:

Check our our Privacy Policy

Code of conduct

Read our code of conduct

PharmaNest proudly participates to the E-Verify program and respects related Immigration Laws.